These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 30502762)

  • 1. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
    Zhou Y; Cao HB; Li WJ; Zhao L
    Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
    Scala S
    Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
    Nazari A; Khorramdelazad H; Hassanshahi G
    Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
    Khare T; Bissonnette M; Khare S
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
    Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
    Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL12 (SDF-1)/CXCR4 pathway in cancer.
    Teicher BA; Fricker SP
    Clin Cancer Res; 2010 Jun; 16(11):2927-31. PubMed ID: 20484021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
    Zhou W; Guo S; Liu M; Burow ME; Wang G
    Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases.
    Liepelt A; Tacke F
    Am J Physiol Gastrointest Liver Physiol; 2016 Aug; 311(2):G203-9. PubMed ID: 27313175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.
    Xu D; Li R; Wu J; Jiang L; Zhong HA
    Curr Top Med Chem; 2016; 16(13):1441-51. PubMed ID: 26369824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?
    Hirbe AC; Morgan EA; Weilbaecher KN
    Curr Pharm Des; 2010; 16(11):1284-90. PubMed ID: 20166978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell.
    Wang Z; Sun J; Feng Y; Tian X; Wang B; Zhou Y
    Tumour Biol; 2016 Jul; 37(7):8515-28. PubMed ID: 27079871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.
    Bao S; Darvishi M; H Amin A; Al-Haideri MT; Patra I; Kashikova K; Ahmad I; Alsaikhan F; Al-Qaim ZH; Al-Gazally ME; Kiasari BA; Tavakoli-Far B; Sidikov AA; Mustafa YF; Akhavan-Sigari R
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7945-7968. PubMed ID: 36905421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy.
    Mousavi A
    Immunol Lett; 2020 Jan; 217():91-115. PubMed ID: 31747563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokine receptor CXCR4: role in gastrointestinal cancer.
    Lombardi L; Tavano F; Morelli F; Latiano TP; Di Sebastiano P; Maiello E
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):696-705. PubMed ID: 24120239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.
    Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J
    Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The good and bad faces of the CXCR4 chemokine receptor.
    Teixidó J; Martínez-Moreno M; Díaz-Martínez M; Sevilla-Movilla S
    Int J Biochem Cell Biol; 2018 Feb; 95():121-131. PubMed ID: 29288743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
    Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
    Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.
    Sun X; Cheng G; Hao M; Zheng J; Zhou X; Zhang J; Taichman RS; Pienta KJ; Wang J
    Cancer Metastasis Rev; 2010 Dec; 29(4):709-22. PubMed ID: 20839032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions.
    Huynh C; Dingemanse J; Meyer Zu Schwabedissen HE; Sidharta PN
    Pharmacol Res; 2020 Nov; 161():105092. PubMed ID: 32758634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
    Burger JA; Stewart DJ; Wald O; Peled A
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.